DGAP-News: MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis
|
DGAP-News: MorphoSys AG
/ Key word(s): Miscellaneous/Conference
MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis 12.12.2021 / 15:00 The issuer is solely... |